DOACs and Urgent Bleeding

Slides:

Advertisements

Similar presentations

Bleeding complications and management in patients treated with NOACs

Advertisements

ANNEXA™-R Part 2: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Sustained Reversal of Rivaroxaban-Induced Anticoagulation.

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.

Pharmacokinetic and Pharmacodynamic Modeling of Andexanet Alfa Dose to Reverse the Anticoagulant Activity of FXa Inhibitors in Patients With Acute Major.

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.

Fadiea Al-Aieshy PhD-student, MSc Pharm

Addressing the Challenges in Primary and Secondary Stroke Prevention

Volume 28, Issue 6, Pages (December 2012)

Anticoagulation in Atrial Fibrillation

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

Oral Anticoagulants and Reversal Agents

Anticoagulants in Interventional Cardiology:

Anticoagulant Review Morning Report – April 25, 2018

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

Pharmacology of Anticoagulants

Thrombosis, Cancer, and NOACs

Access to NOAC Therapy:

New Strategies to Prevent CV Events After Hospital Discharge

Emergency Management of NOAC Bleeding

A New Era for NOACs:.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF

Unmet Needs in the Secondary Prevention in ACS

Anticoagulation Highlights From the American Heart Association Meeting 2017.

New Perspectives in AF and PCI: Implications for the Practicing Physician.

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Extended Half-life Factor Products in the Management of Hemophilia

REVERSAL AGENTS FOR NOACS: Do WE NEED THEM in THE EP LAB?

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Oral Anticoagulants in AFa,b A Brief History.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

The Essentials for Secondary Stroke Prevention

Reversal of Direct Oral Anticoagulants (DOAC)

“Reversing Direct Oral Anticoagulants”

New Oral Anticoagulants and VTE Management

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.

Access to NOAC Therapy:

Adherence in SPAF: Measures to Improve Care

Reversal Strategies for VKA: Truths and Misconceptions

Risk Stratification in CAD and PAD

Oral Anticoagulation in AF

Dos and Don’ts for High-Risk Elderly Patients With AF

Atrial Fibrillation.

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Neurosurgery and DOACs

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

Oral Anticoagulant Reversal Agents

What You Didn't Know About AF and Renal Dysfunction

Cancer-Associated Thrombosis

Anticoagulant Reversal

A Case Challenge.

New European Anticoagulant Approvals Will They Affect Practical Guidance?

Extended Half-life Factor Products in the Management of Hemophilia

Periprocedural Management of Patients on Anticoagulation

Which NOAC and When for Stroke Prevention in AF?

Antithrombotic Therapy in Vascular Protection: From CAD to HF

 INDICATIONS AND USAGE  DOSAGE AND ADMINISTRATION  DOSAGE FORMS AND STRENGTHS  WARNINGS AND PRECAUTIONS  ADVERSE REACTIONS  USE IN SPECIFIC POPULATIONS.

Nat. Rev. Cardiol. doi: /nrcardio

Program Goals Background: Anticoagulation in Patients With VTE.

Factor Xa Inhibitors in Coronary Artery Disease

NOACs and Reversal Agents

AMD Therapy: Where Are We Now and Where Are We Going?

RE-ALIGN Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients after Heart Valve Replacement.

Drug Summary Info Document Request / monitor Goal of therapy Action

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Presentation transcript:

DOACs and Urgent Bleeding

Overview

Management of DOAC Bleeding In the Absence of Reversal Agents

Pharmacokinetics of DOACs

US Indications and Dosage

Bleeding With DOACs

Less Harm With DOACs -- Bleed Prevention

DOACs Bleeding Events Systematic Review and Meta-Analysis

Outcomes of Patients With Major Bleeding Dabigatran vs Warfarin

Candidates for Reversal Agents

Prior to Reversal Factors to Consider

Reversal Agents

Idarucizumab

RE-VERSE AD

Andexanet Alfa

Andexanet Alfa: Recombinant, Modified Version of Human FXa Produced in CHO Cells

ANNEXA-4 Inclusion/Exclusion Criteria

ANNEXA-4 Results

ANNEXA-4 Interim Analysis

ANNEXA-4 Interim Analysis (cont)

Change in Anti-FXa Activity (ng/mL) in Subjects Anticoagulated with Apixaban

Change in Anti-FXa Activity (ng/mL) in Subjects Anticoagulated With Rivaroxaban

The Bleeding Has Stopped -- What's Next?

Reversal Agents Practical Considerations

Supply and Distribution

Summary

Abbreviations

Abbreviations (cont)